Skip to main content

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

Terminated · Not applicable · NCT02928497

Conditions: Stroke

At a glance

Research payments reported, 2025
$217,768
U.S. investigators named
50
Sites paid
51
Planned or actual enrollment
481

About the trial

Sponsor
Boston Scientific Corporation
Tested
WATCHMAN LAAC Device Implant (device), Single Antiplatelet Therapy or No Therapy (Control) (drug)
Dates
Started 2017-02-06; completion 2025-09-23
Results posted
Yes

The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.

From ClinicalTrials.gov, last updated 2026-08-25. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $217,768 in research payments for this study in 2025 (160 payments).

Products named: Watchman Access System

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.